{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:58:28Z","timestamp":1793163508759,"version":"4.5.0"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100012665","name":"Institute for Clinical Evaluative Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health and Long-Term Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010564","name":"Academic Medical Organization of Southwestern Ontario","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008093","name":"Schulich School of Medicine and Dentistry","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008093","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Western University, and the Lawson Health Research Institute"},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients undergoing treatment for cancer are at increased risk of acute kidney injury (AKI). There are few data on AKI incidence and risk factors in the current era of cancer treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a population-based study of all patients initiating systemic therapy (chemotherapy or targeted agents) for a new cancer diagnosis in Ontario, Canada (2007\u20132014). The primary outcome was hospitalization with AKI or acute dialysis. We estimated the cumulative incidence of AKI and fitted Fine and Gray models, adjusting for demographics, cancer characteristics, comorbidities, and coprescriptions. We modeled exposure to systemic therapy (the 90-day period following treatments) as a time-varying covariate. We also assessed temporal trends in annual AKI incidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 163\u2009071 patients initiating systemic therapy of whom 10\u2009880 experienced AKI. The rate of AKI was 27 per 1000 person-years, with overall cumulative incidence of 9.3% (95% CI = 9.1% to 9.6%). Malignancies with the highest 5-year AKI incidence were myeloma (26.0%, 95% CI = 24.4% to 27.7%), bladder (19.0%, 95% CI = 17.6% to 20.5%), and leukemia (15.4%, 95% CI = 14.3% to 16.5%). Advanced cancer stage, chronic kidney disease, and diabetes were associated with increased risk of AKI (adjusted hazard ratios [aHR] = 1.41, 95% CI = 1.28 to 1.54; 1.80, 95% CI = 1.67 to 1.93; and 1.43, 95% CI = 1.37 to 1.50, respectively). In patients aged 66 years or older with universal drug benefits, diuretic, and angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker coprescription was associated with higher AKI risk (aHR = 1.20, 95% CI = 1.14 to 1.28; 1.30, 95% CI = 1.23 to 1.38). AKI risk was further accentuated during the 90-day period following systemic therapy (aHR = 2.34, 95% CI = 2.24 to 2.45). The annual incidence of AKI increased from 18 to 52 per 1000 person-years between 2007 and 2014.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Cancer-related AKI is common and associated with advanced stage, chronic kidney disease, diabetes, and concomitant receipt of diuretics or angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers. Risk is heightened in the 90\u2009days after systemic therapy. Preventive strategies are needed to address the increasing burden of AKI in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djy167","type":"journal-article","created":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T23:58:12Z","timestamp":1535155092000},"page":"727-736","source":"Crossref","is-referenced-by-count":132,"title":["Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study"],"prefix":"10.1093","volume":"111","author":[{"given":"Abhijat","family":"Kitchlu","sequence":"first","affiliation":[{"name":"Department of Medicine"},{"name":"Division of Nephrology, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"McArthur","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Amir","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M","family":"Booth","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences, London, ON, Canada"},{"name":"Department of Oncology, Queen's University, Kingston, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinku","family":"Sutradhar","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences, London, ON, Canada"},{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habeeb","family":"Majeed","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M","family":"Nash","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A","family":"Silver","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Queen's University, Kingston, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit X","family":"Garg","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences, London, ON, Canada"},{"name":"Division of Nephrology, Western University, London, ON, Canada (AXG)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T","family":"Chan","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S Joseph","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Toronto, Toronto, ON, Canada"},{"name":"Institute for Clinical Evaluative Sciences, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Wald","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"issue":"5","key":"2019071119554755600_djy167-B1","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1053\/j.ajkd.2015.04.042","article-title":"Onco-nephrology: core curriculum 2015","volume":"66","author":"Cohen","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"2019071119554755600_djy167-B2","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1038\/sj.bjc.6605979","article-title":"Cancer and renal insufficiency results of the BIRMA study","volume":"103","author":"Janus","year":"2010","journal-title":"Br J Cancer"},{"issue":"10","key":"2019071119554755600_djy167-B3","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.03140312","article-title":"Onco-nephrology: AKI in the cancer patient","volume":"7","author":"Lam","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"18","key":"2019071119554755600_djy167-B4","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMra1613984","article-title":"Acute kidney injury in patients with cancer","volume":"376","author":"Rosner","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"2019071119554755600_djy167-B5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/cc4907","article-title":"Clinical review: specific aspects of acute renal failure in cancer patients","volume":"10","author":"Darmon","year":"2006","journal-title":"Crit Care"},{"issue":"1","key":"2019071119554755600_djy167-B6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/07853890510007205","article-title":"Acute renal failure in cancer patients","volume":"37","author":"Lameire","year":"2005","journal-title":"Ann Med"},{"key":"2019071119554755600_djy167-B7","author":"Lahoti"},{"issue":"5","key":"2019071119554755600_djy167-B8","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00134-007-0579-1","article-title":"Should dialysis be offered to cancer patients with acute kidney injury?","volume":"33","author":"Darmon","year":"2007","journal-title":"Intensive Care Med"},{"issue":"12","key":"2019071119554755600_djy167-B9","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1093\/ndt\/gfv372","article-title":"Acute kidney injury in critically ill patients with haematological malignancies: results of a multicentre cohort study from the Groupe de Recherche en R\u00e9animation Respiratoire en Onco-H\u00e9matologie","volume":"30","author":"Darmon","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"17","key":"2019071119554755600_djy167-B10","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1002\/cncr.25306","article-title":"Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome","volume":"116","author":"Lahoti","year":"2010","journal-title":"Cancer"},{"issue":"3\u20134","key":"2019071119554755600_djy167-B11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000329042","article-title":"Predicting hospital mortality in critically ill cancer patients according to acute kidney injury severity","volume":"80","author":"Lib\u00f3rio","year":"2011","journal-title":"Oncology"},{"issue":"24","key":"2019071119554755600_djy167-B12","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2006.05.7869","article-title":"Prognosis of critically ill patients with cancer and acute renal dysfunction","volume":"24","author":"Soares","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019071119554755600_djy167-B13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2215\/CJN.03530412","article-title":"Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center","volume":"8","author":"Salahudeen","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2019071119554755600_djy167-B14","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/cc2872","article-title":"Acute renal failure\u2014definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group","volume":"8","author":"Bellomo","year":"2004","journal-title":"Crit Care"},{"issue":"4","key":"2019071119554755600_djy167-B15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ejim.2011.05.005","article-title":"Incidence of acute kidney injury in cancer patients: a Danish population-based cohort study","volume":"22","author":"Christiansen","year":"2011","journal-title":"Eur J Intern Med"},{"issue":"5","key":"2019071119554755600_djy167-B16","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1681\/ASN.2014090876","article-title":"ESRD due to multiple myeloma in the United States, 2001-2010","volume":"27","author":"Reule","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2019071119554755600_djy167-B17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.critrevonc.2017.02.007","article-title":"How have evolutions in strategies for the treatment of relapsed\/refractory multiple myeloma translated into improved outcomes for patients?","volume":"112","author":"Sonneveld","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"2019071119554755600_djy167-B18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ctrv.2016.09.002","article-title":"Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy","volume":"50","author":"Calvo","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"2019071119554755600_djy167-B19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/nrneph.2017.82","article-title":"Targeted therapies for renal cell carcinoma","volume":"13","author":"Posadas","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"2019071119554755600_djy167-B20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11523-015-0368-7","article-title":"Renal toxicities of targeted therapies","volume":"10","author":"Abbas","year":"2015","journal-title":"Target Oncol"},{"issue":"2","key":"2019071119554755600_djy167-B21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00345-016-1868-5","article-title":"Systemic therapy in metastatic renal cell carcinoma","volume":"35","author":"Bedke","year":"2017","journal-title":"World J Urol"},{"issue":"8","key":"2019071119554755600_djy167-B22","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/annonc\/mdv136","article-title":"Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN)","volume":"26","author":"Launay-Vacher","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"2019071119554755600_djy167-B23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.ackd.2017.05.006","article-title":"Kidney toxicities associated with novel cancer therapies","volume":"24","author":"Lefebvre","year":"2017","journal-title":"Adv Chronic Kidney Dis"},{"issue":"11","key":"2019071119554755600_djy167-B24","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/0277-5379(91)90041-B","article-title":"Cancer incidence registration and trends in Ontario","volume":"27","author":"McLaughlin","year":"1991","journal-title":"Eur J Cancer"},{"key":"2019071119554755600_djy167-B25","volume-title":"Ontario Cancer Statistics","author":"Cancer Care Ontario","year":"2016"},{"key":"2019071119554755600_djy167-B26"},{"issue":"5","key":"2019071119554755600_djy167-B27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"6","key":"2019071119554755600_djy167-B28","doi-asserted-by":"crossref","first-page":"e001821","DOI":"10.1136\/bmjopen-2012-001821","article-title":"Validity of the International Classification of Diseases, Tenth Revision code for acute kidney injury in elderly patients at presentation to the emergency department and at hospital admission","volume":"2","author":"Hwang","year":"2012","journal-title":"BMJ Open"},{"issue":"4","key":"2019071119554755600_djy167-B29","doi-asserted-by":"crossref","first-page":"682","DOI":"10.2215\/CJN.07650713","article-title":"Performance and limitations of administrative data in the identification of AKI","volume":"9","author":"Grams","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"2019071119554755600_djy167-B30","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/MLR.0b013e3181e419fd","article-title":"Using administrative datasets to study outcomes in dialysis patients: a validation study","volume":"48","author":"Quinn","year":"2010","journal-title":"Med Care"},{"issue":"6","key":"2019071119554755600_djy167-B31","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1053\/j.ajkd.2014.10.017","article-title":"Changing incidence and outcomes following dialysis-requiring acute kidney injury among critically ill adults: a population-based cohort study","volume":"65","author":"Wald","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"446","key":"2019071119554755600_djy167-B32","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"2019071119554755600_djy167-B33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/10428190601126602","article-title":"Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance","volume":"48","author":"Eleutherakis-Papaiakovou","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2019071119554755600_djy167-B34","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.2215\/CJN.01640216","article-title":"Paraprotein-related kidney disease: evaluation and treatment of myeloma cast nephropathy","volume":"11","author":"Finkel","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2019071119554755600_djy167-B35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/j.ackd.2013.08.009","article-title":"Myeloma-related kidney disease","volume":"21","author":"Leung","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"issue":"1","key":"2019071119554755600_djy167-B36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/annonc\/mdt483","article-title":"Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents","volume":"25","author":"Dimopoulos","year":"2014","journal-title":"Ann Oncol"},{"key":"2019071119554755600_djy167-B37","first-page":"CD010816.","article-title":"Bortezomib for the treatment of multiple myeloma","volume":"4","author":"Scott","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"2019071119554755600_djy167-B38","doi-asserted-by":"crossref","first-page":"e101819.","DOI":"10.1371\/journal.pone.0101819","article-title":"The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment","volume":"9","author":"Uttervall","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"2019071119554755600_djy167-B39","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ajh.24335","article-title":"Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis","volume":"91","author":"Dimopoulos","year":"2016","journal-title":"Am J Hematol"},{"issue":"5","key":"2019071119554755600_djy167-B40","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1634\/theoncologist.2010-0225","article-title":"The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future","volume":"16","author":"Pozzi","year":"2011","journal-title":"Oncologist"},{"issue":"1","key":"2019071119554755600_djy167-B41","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1053\/j.ackd.2013.08.002","article-title":"Acute kidney injury in the cancer patient","volume":"21","author":"Campbell","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"issue":"7","key":"2019071119554755600_djy167-B42","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.08070715","article-title":"Long-term renal outcomes after cisplatin treatment","volume":"11","author":"Latcha","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2019071119554755600_djy167-B43","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1245\/s10434-015-4886-4","article-title":"Acute kidney injury after radical cystectomy for bladder cancer is associated with chronic kidney disease and mortality","volume":"23","author":"Kwon","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"2019071119554755600_djy167-B44","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"30","author":"De Santis","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019071119554755600_djy167-B45","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.eururo.2006.12.029","article-title":"Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: Results of a randomized phase 2 trial","volume":"52","author":"Dogliotti","year":"2007","journal-title":"Eur Urol"},{"issue":"1","key":"2019071119554755600_djy167-B46","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/j.ackd.2013.07.004","article-title":"Kidney involvement in leukemia and lymphoma","volume":"21","author":"Luciano","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"issue":"1","key":"2019071119554755600_djy167-B47","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.ackd.2013.08.007","article-title":"The kidney effects of hematopoietic stem cell transplantation","volume":"21","author":"Sawinski","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"issue":"12","key":"2019071119554755600_djy167-B48","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/bmt.2013.109","article-title":"Long-term outcome of patients with multiple [corrected] myeloma-related advanced renal failure following auto-SCT","volume":"48","author":"Glavey","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2019071119554755600_djy167-B49","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.bbmt.2009.03.021","article-title":"Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma","volume":"15","author":"Parikh","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019071119554755600_djy167-B50","doi-asserted-by":"crossref","first-page":"181.","DOI":"10.1186\/1471-2369-15-181","article-title":"Impact of partial nephrectomy on kidney function in patients with renal cell carcinoma","volume":"15","author":"Kim","year":"2014","journal-title":"BMC Nephrol"},{"issue":"7","key":"2019071119554755600_djy167-B51","doi-asserted-by":"crossref","first-page":"293.e1","DOI":"10.1016\/j.urolonc.2016.02.018","article-title":"Trends of acute kidney injury after radical or partial nephrectomy for renal cell carcinoma","volume":"34","author":"Schmid","year":"2016","journal-title":"Urol Oncol"},{"issue":"4","key":"2019071119554755600_djy167-B52","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ekir.2017.02.008","article-title":"Anticancer drug-induced acute kidney injury","volume":"2","author":"Izzedine","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"4","key":"2019071119554755600_djy167-B53","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1183\/09031936.00055110","article-title":"Cisplatin nephrotoxicity aggravated by cardiovascular disease and diabetes in lung cancer patients","volume":"37","author":"M\u00e1th\u00e9","year":"2011","journal-title":"Eur Respir J"},{"issue":"10","key":"2019071119554755600_djy167-B54","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2215\/CJN.02780312","article-title":"Onco-nephrology: renal toxicities of chemotherapeutic agents","volume":"7","author":"Perazella","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8 suppl","key":"2019071119554755600_djy167-B55","first-page":"26","article-title":"Management of comorbid diabetes and cancer","volume":"21","author":"Singer","year":"2007","journal-title":"Oncology (Williston Park)"},{"issue":"5","key":"2019071119554755600_djy167-B56","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamainternmed.2015.0289","article-title":"Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness","volume":"175","author":"Kutner","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"7","key":"2019071119554755600_djy167-B57","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1016\/S1470-2045(15)00080-7","article-title":"Polypharmacy in patients with advanced cancer and the role of medication discontinuation","volume":"16","author":"LeBlanc","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"2019071119554755600_djy167-B58","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.cllc.2014.12.003","article-title":"Comorbidity in patients with small-cell lung cancer: trends and prognostic impact","volume":"16","author":"Aarts","year":"2015","journal-title":"Clin Lung Cancer"},{"issue":"32","key":"2019071119554755600_djy167-B59","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1200\/JCO.2015.63.0319","article-title":"Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology Statement","volume":"33","author":"Hurria","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019071119554755600_djy167-B60","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/bjc.2012.46","article-title":"Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality","volume":"106","author":"Jorgensen","year":"2012","journal-title":"Br J Cancer"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/111\/7\/727\/28924632\/djy167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T04:45:11Z","timestamp":1569213911000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/111\/7\/727\/5181304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,13]]},"references-count":60,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,11,13]]},"published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djy167","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2018,11,13]]}}}